Table 3.
Adherence to trial medication during follow‐up
| Placebo | Simvastatin | Overall | |
|---|---|---|---|
| 3‐month visit | |||
| No. of patients | 13 | 14 | 27 |
| No. with adherence ≥ 80% | 6 | 8 | 14 |
| Adherence (%)* | 77 (38–98) | 85 (63–99) | 83 (45–98) |
| 6‐month visit | |||
| No. of patients | 10 | 8 | 18 |
| No. with adherence ≥ 80% | 8 | 6 | 14 |
| Adherence (%)* | 94 (90–100) | 92 (67–99) | 94 (83–100) |
| 9‐month visit | |||
| No. of patients | 5 | 5 | 10 |
| No. with adherence ≥ 80% | 5 | 5 | 10 |
| Adherence (%)* | 97 (96–99) | 100 (99–100) | 99 (96–100) |
| 12‐month visit | |||
| No. of patients | 3 | 5 | 8 |
| No. with adherence ≥ 80% | 2 | 4 | 6 |
| Adherence (%)* | 92 (78–98) | 96 (85–100) | 94 (82–99) |
*
Median (i.q.r.) percentage adherence to at least 80 per cent of trial medication in the preceding 3 months. No implausible values for adherence (greater than 105 per cent) were observed at 3 months. Values from three patients were ignored at 6 months (and thereafter), values from five patients were ignored at 9 months (and thereafter) and none were ignored at 12 months.